novoCare Quiz

Insulin detemir (IDet) differs from human insulin

• with the omission of aspartic acid at position 30 and attachment of myristic acid at position 29 by acylation.

• with the additon of threonine at position 30 and attachment of myristic acid at position 30 by acylation.

• with the omission of threonine at position 30 and attachment of myristic acid at position 29 by acylation.

• with the omission of proline at position 29 and attachment of myristic acid at position 29 by acylation.

Insulin Detemir is produced by a process including recombinant DNA technology using

• Saccharomyces cerevisiae

• E. Coli

• Both A & B

What are the main mechanisms underlying the prolonged action of insulin determir.

• Increased insulin self-association in the subcutaneous depot

• interstitial albumin binding

• plasma albumin binding

• All of above

While insulin detemir is

• hexameric upon injection

• dimeric upon injection

• monomeric upon injection

  none of above

• none of above

Once in the bloodstream

• 99% of these monomers bind to plasma albumin

• 100% of these monomers bind to plasma albumin

• >98% of these monomers bind to plasma albumin

• 97% of these monomers bind to plasma albumin

In insulin aspart, substitution of amino acid ________ with ________ at position _____ is done.

• Arginine – Aspartic Acid – A28.

• Proline – Aspartic Acid – B28.

• Glycine – Myristic Acid – B23

• Lysine – Glutamic Acid – B30

NovoMix® 30 should only be administered?

• Subcutaneously

• Intra muscular injection

• Intra venous injection

• Both a and b

What is most common undesirable effect of NovoMix®?

• Neuropathy

• Retinopathy

• Hypoglycaemia

• Nephropathy

What is the mechanism of action of NovoMix® 30?

a) Facilitated uptake of glucose following binding of insulin to receptors on muscle and fat cells.

b) Increase Incretin effect

c) Inhibition of hepatic glucose output

d) Both A & C

• Facilitated uptake of glucose following binding of insulin to receptors on muscle and fat cells.

• Increase Incretin effect

• Inhibition of hepatic glucose output

• Both A & C

The onset of action of BiAsp 30 is:

• 30-40 minutes

• 30-40 minutes

• 10-20 minutes

• 5-8 minutes